Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Irish businesses back global vaccine drive
This article summarises the companies, including ICON, who are backing UNICEF’s drive to supply 2 billion vaccines to the developing world.
-
The changing pace of vaccines: How COVID-19 has impacted the future of infectious disease vaccine development
Shelley McLendon considers the knock-on effect of COVID-19 for other infectious diseases, and what we can do to speed up development future vaccines
-
Morning Ireland business news
In this radio interview briefly discusses the disparity of vaccine rollouts of developed countries compared to less economically developed countries, and the role of ICON
-
The bottom line: Clinical trials
Nuala Murphy contributes to the Bottom Line BBC4 podcast about the impact of the COVID-19 vaccine on the clinical trial process and whether these changes could work for other drugs.
-
A trusted partner for clinical development
ICON CEO Steve Cutler chats with Newsweek, on ICON’s role in the development of much needed medicines. The interview (page 12 of PDF) is part of a special report on Ireland.
-
Smart people: Dr. Steve Cutler
PharmaTimes talks to Dr Steve Cutler, CEO at ICON plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials.
-
Global collaboration: Irish company ICON on scaling up COVID-19 vaccine trials
An interview in which Steve Cutler gives a short overview of ICON and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.
-
The effect of Covid-19 solutions on the clinical trials process
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
-
-
US Regulators question AstraZeneca vaccine trial data
ICON's Dr. Andrew Garrett, Executive Vice President of Scientific Operations, weighs in on potential safety issues with the AstraZeneca COVID-19 vaccine.
